Thank you
This live web event has ended. Thank you for attending.
Description
Making Certain We Get the Right Cervical Disease Diagnosis
for Our Patients: Results of the CERTAIN Study
Why should you register now for this webinar?
Hear a national thought leader discuss cervical disease diagnosis
Brought to you by: CAP TODAY
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Presenter: Thomas C. Wright, Jr., MD
Presented in this CAP TODAY webinar is the landmark CERTAIN (CERvical TissueAdjunctIve
aNalysis) study which supported the CINtec® Histology 510(k) FDA clearance in the U.S.
The CERTAIN study is one of the largest immunohistochemistry clinical studies conducted
to date, with more than 38,500 slide interpretations by 70 participating pathologists.
Based on the p16 biomarker, the CINtec® Histology test used along with H&E improved the
diagnostic agreement and consistency of high-grade cervical disease in cervical biopsies
across all pathologists.
The CINtec® Histology test as an adjunct to H&E helps pathologists and practitioners be
certain the right patient is treated without unnecessary overtreatment of more patients.
Ask questions of our distinguished presenter.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.